{"id":"W4402565845","doi":"10.1016/j.annonc.2024.08.2325","title":"LBA82 Efficacy and safety of ponsegromab, a first-in-class, monoclonal antibody inhibitor of growth differentiation factor 15, in patients with cancer cachexia: A randomized, placebo-controlled, phase II study","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"GDF15 and Related Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Monoclonal antibody; Cachexia; Placebo; Oncology; Cancer cachexia; Internal medicine; Monoclonal; Randomized controlled trial; Phases of clinical research; Cancer; Antibody; Clinical trial; Immunology; Pathology; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005908899,0.0002054164,0.001568657,0.0004823951,0.00002707613,0.000003518495,0.00006125342,0.0002213594,0.00005223809],"category_scores_gemma":[0.0002732925,0.0001319497,0.0001440053,0.0003390239,0.0002260267,0.00006811786,0.00004952037,0.000246006,4.380465e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006102383,"about_ca_system_score_gemma":0.0002765249,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005412128,"about_ca_topic_score_gemma":0.0003666448,"domain_scores_codex":[0.9979847,0.0003060974,0.0009128609,0.0002962237,0.0002735235,0.0002265702],"domain_scores_gemma":[0.9984757,0.0007781962,0.0003326642,0.0001266968,0.0002081554,0.00007861072],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8023583,0.009296051,0.1760668,0.0003769552,0.001901254,0.00006339215,0.003133245,0.00001207825,0.002170135,0.00002675428,0.0001509611,0.004444117],"study_design_scores_gemma":[0.6442495,0.01268055,0.3399695,0.000694161,0.000479667,0.000003832798,0.0002048932,0.0006362377,0.0009101133,0.00001440207,0.00004100814,0.0001161221],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9939696,0.001440459,0.000007493633,0.001263815,0.0001617002,0.002911998,0.00007548153,0.00001138082,0.00015804],"genre_scores_gemma":[0.999162,0.000578264,0.000023499,0.00003277848,0.00002581848,0.00007447187,0.00004277019,0.00001743885,0.00004301856],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1639028,"threshold_uncertainty_score":0.5380751,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01770669949229705,"score_gpt":0.339244890681104,"score_spread":0.3215381911888069,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}